News

  • 18 September 2013

    Creabilis, a late clinical stage European dermatology company with a focus on pruritus (itch), today announces it has treated the first patients in its Phase 2b study of its lead product, CT327, in patients with atopic dermatitis (AD).

  • 18 September 2013

    Diagnoplex SA, a developer of molecular diagnostics for colorectal cancer and Unilabs, a leading supplier of clinical laboratory and medical diagnostic imaging services in Europe, signed a collaboration agreement to commercialize Colox®, a minimally invasive colorectal cancer assay within the Unilabs network. The test will be available initially in the Swiss and Swedish markets.

  • 16 September 2013

    JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today it has received CE (Conformité Européenne) Mark approval from European regulators for its transapical TAVI system for the treatment of aortic insufficiency (AI), a condition also known as aortic regurgitation in which the native aortic valve does not close properly, allowing blood to leak back into the left ventricle of the heart.

  • 3 September 2013

    Sonendo®, the developer of a revolutionary technology for the endodontic marketplace, announced today that the company has received 510(k) FDA clearance for the first generation of its Multisonic Ultracleaning System™ set to launch in 2014.  The device is designed to be a minimally invasive, disruptive technology that uses multiple wavelengths of sound to simultaneously clean the entire root canal system.

  • 3 September 2013

    Arsanis Inc, a privately-held biotechnology company developing human monoclonal antibodies for severe infectious diseases, today announced that it has raised $20 million in a Series B financing.